CartilaGen
Phase 2CG-001 is an investigational therapy designed to address oxidative stress that occurs following ankle fractures and other traumatic skeletal injuries, with the ultimate goal of reducing the risk of Post-Traumatic Osteoarthritis (also known as PTOA).
Founded
2018
Focus
Small Molecules
About
CG-001 is an investigational therapy designed to address oxidative stress that occurs following ankle fractures and other traumatic skeletal injuries, with the ultimate goal of reducing the risk of Post-Traumatic Osteoarthritis (also known as PTOA).
Funding History
1Total raised: $5M
Seed$5MUndisclosedMar 15, 2021
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile